RxDoctor Payments Data

Margaret Reiker

Internal Medicine · Saint Louis, MONPI 1902915853

Payments from drug & device makers

$6,977in general payments, 2019–2025

Across 411 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$904
  • Lilly USA, LLC$667
  • Pfizer$561
  • Amgen$491
  • GSK$328
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,965100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,977 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$139,856
Medicare patients
451
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$117,597
OzempicSemaglutide57$70,945
RybelsusSemaglutide37$66,982
FarxigaDapagliflozin Propanediol61$61,769
MounjaroTirzepatide48$57,955
TrulicityDulaglutide25$57,751
XareltoRivaroxaban25$26,403
JardianceEmpagliflozin23$23,970
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,223
LinzessLinaclotide14$15,952
SymbicortBudesonide/Formoterol Fumarate45$14,013
MyrbetriqMirabegron11$13,331
ArexvyRsvpref3 Antigen/As01e/Pf48$12,327
Tresiba Flextouch U-100Insulin Degludec14$11,630
SynthroidLevothyroxine Sodium115$10,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$904$137,92794 claims
PfizerEliquis, Abrysvo, Paxlovid$561$124,980172 claims
Lilly USA, LLCMounjaro, Trulicity$667$115,70773 claims
AstraZenecaFarxiga, Symbicort$209$75,782106 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta$328$42,92295 claims
Boehringer IngelheimJardiance, Spiriva Respimat$16$31,16037 claims
AbbVieLinzess, Synthroid$1,247$26,499129 claims
Johnson & JohnsonXarelto$82$26,40325 claims
Astellas Pharma US IncMyrbetriq$30$13,33111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →